Company news

Amplia Therapeutics Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Amplia Receives Ethics Clearance fo Conduct Phase 1 Trial

September 7, 2020

Quarterly Activities and Cashflow Reports - June 2020

July 26, 2020

Nucleus Network Appointed to Conduct Phase 1 Clinical Trial

July 22, 2020

Institutional Entitlement Offer Completed

July 2, 2020

Capital Raising - Investor Presentation

July 1, 2020

Entitlement Offer to Fund Phase 1 Clinical Trial

June 30, 2020

Preliminary Toxicology Studies Support Phase1 Clinical Trial

June 30, 2020

Preliminary Final Report - YE 31 March 2020

May 29, 2020

FDA Orphan Drug Designation - Idiopathic Pulmonary Fibrosis

May 19, 2020

Quarterly Activities Report - March 2020 Qtr

April 27, 2020

App 4C - Quarterly Cash Flow Report - March 2020 Qtr

April 27, 2020

FDA Awards Orphan Drug Designation for Pancreatic Cancer

March 24, 2020

Dr. John Lambert appointed as Managing Director

February 6, 2020

Appendix 4C Cash Flow - Dec 2019 Qtr

January 29, 2020

Amplia Therapeutics Undertakes Placement

January 19, 2020

App 4D - Financial Report Half Year Ended 30 Sep 2019

November 29, 2019

App 4C - Sep 2019 Qtr Cash Flows Statement

October 31, 2019

Appendix 4C - Quarterly Cash Flow Report - June 2019 Qtr

July 31, 2019

RightsIssue Participation Supports Clinical-Enabling Studies

July 31, 2019

Amplia Therapeutics Reports Lead Candidate Preclinical Data

July 23, 2019

Rights Issue Prospectus

June 27, 2019

Dr John Lambert appointed as new CEO

June 24, 2019

Capital Raising for Clinical-Enabling Studies

June 12, 2019

Preliminary Final Report - Year Ended 31 March 2019

May 29, 2019

Appendix 4C - Quarterly Statement of Cash Flows

April 29, 2019

European Patent Completes IP Protection in Major Markets

March 31, 2019

Appendix 4C - December 2018 Quarter Cashflow Statement

January 28, 2019

App 4D Half Year Accounts 30 Sep 2018

November 28, 2018

Appendix 4C - quarterly

October 30, 2018

Response to ASX Query

August 14, 2018

Appendix 4C - June 2018 Quarter Cashflow Statement

July 30, 2018

European Patent Granted for Innates Drug Candidate AMP-886

July 22, 2018

Preliminary Final Report - Year Ended 31 March 2018

May 30, 2018

App 4C - March 2018 Quarterly Cash Flow Report

April 30, 2018

Focus on Immuno-Oncology & Acquisition of 2 Drug Candidates

March 22, 2018

S&P DJ Indices Announces March Quarterly Rebalance

March 8, 2018

Appendix 4C - December 2017 Quarter

January 30, 2018

Half Yearly Report and Accounts - HY ending 30 Sep 2017

November 30, 2017

Appendix 4C - September 2017 Quarter Cashflows

October 29, 2017

Corporate Update

October 19, 2017

App 4C - Quarterly Statement of Cashflows - June 2017 Qtr

July 27, 2017

No Change in Trial Outcome Following Additional Analysis

July 20, 2017

Top-Line Results for Trial of MIS416

June 26, 2017

FDA Clearance - MIS416 Investigational New Drug Application

June 20, 2017

Preliminary Final Report - Year Ended 31 March 2017

May 30, 2017

Appendix 4C - March 17 Quarter Statement of Cash Flows

April 28, 2017

Completion of Phase 2B Trial of MIS416

April 19, 2017

Private Placement to raise Additional Working Capital

March 16, 2017

Phase 2B Trial of MIS416 on Schedule to Complete April 2017

February 27, 2017

IIL Panel Declines to Conduct Proceedings

February 19, 2017

← Newer news releases · Older news releases →

Decks

The 5 newest of 37 decks. Every deck is listed under its year.